Dr. Garassino on the Clinical Implications of Tepotinib in METex14-Altered NSCLC
In Partnership With:
Marina Chiara Garassino, MD, professor of Medicine, Hematology and Oncology, The University of Chicago Department of Medicine, discusses the clinical implications of the phase 2 VISION trial evaluating patients with MET exon 14 skipping mutation–positive non–small cell lung cancer.
Marina Chiara Garassino, MD, professor of Medicine, Hematology and Oncology, The University of Chicago Department of Medicine, discusses the clinical implications of the phase 2 VISION trial (NCT02864992) evaluating patients with MET exon 14 (METex14) skipping mutation–positive non–small cell lung cancer (NSCLC).
A subgroup analysis of the VISION trial demonstrated that tepotinib (Tepmetko) elicited robust and durable clinical efficacy in patients aged 75 years and older, which was similar to the efficacy observed in subsets of younger patients.
It is important to be aware that the rare target, METex14, can be present in NSCLC histologies other than adenocarcinoma, according to Garassino. Additionally, prolonged responses can be established in this patient population with MEK and PARP inhibitors, Garassino continues. Tepotinib should be considered instead of chemotherapy in this patient population, Garassino concludes.
